Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CD123+CLL-1 CAR-T(Hematology Hospital of Chinese Academy of Medical Sciences) in Relapsing acute myeloid leukemia: NCT07201727 Clinical Landscape Report 2026
15 October 2026
NCT07201727 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
PF-08052667 in Non-Muscle Invasive Bladder Neoplasms: NCT07206225 Clinical Landscape Report 2026
15 October 2026
NCT07206225 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
ATTO-3712 in Dermatitis, Atopic: NCT07205081 Clinical Landscape Report 2026
15 October 2026
NCT07205081 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Disitamab Vedotin in HER2-Expressing Non-Muscle Invasive Bladder Neoplasms: NCT07207824 Clinical Landscape Report 2026
15 October 2026
NCT07207824 clinical landscape for HER2-Expressing Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and d…
9 min read
Lenalidomide in Refractory Multiple Myeloma: NCT07210047 Clinical Landscape Report 2026
15 October 2026
NCT07210047 clinical landscape for Refractory Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Locally Advanced Cervical Carcinoma: NCT07205497 Clinical Landscape Report 2026
15 October 2026
NCT07205497 clinical landscape for Locally Advanced Cervical Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Revumenib in Acute Myeloid Leukemia: NCT07212023 Clinical Landscape Report 2026
15 October 2026
NCT07212023 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Revumenib in Acute Myeloid Leukemia: NCT07211958 Clinical Landscape Report 2026
15 October 2026
NCT07211958 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SHR-1905 in Moderate Atopic Dermatitis: NCT07211542 Clinical Landscape Report 2026
15 October 2026
NCT07211542 clinical landscape for Moderate Atopic Dermatitis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ublituximab in Multiple sclerosis relapse: NCT07211633 Clinical Landscape Report 2026
15 October 2026
NCT07211633 clinical landscape for Multiple sclerosis relapse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
INCB123667 in Platinum-Resistant Ovarian Carcinoma: NCT07214779 Clinical Landscape Report 2026
15 October 2026
NCT07214779 clinical landscape for Platinum-Resistant Ovarian Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Fludarabine Phosphate in Acute Myeloid Leukemia: NCT07214688 Clinical Landscape Report 2026
15 October 2026
NCT07214688 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.